IXC 5.71% 7.4¢ invex therapeutics ltd

Ann: Invex to close IIH Evolve Phase III Clinical Trial, page-39

  1. 1,365 Posts.
    lightbulb Created with Sketch. 280
    The raise of $20+ million post phase II trial, and Tattarang as a sub holder (along with Sinclair as a genuine leader in the field) did not scream red flags but obviously there was something there we all missed
    Last edited by BalkanBroker: 22/08/23
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
7.4¢
Change
0.004(5.71%)
Mkt cap ! $5.561M
Open High Low Value Volume
7.1¢ 7.5¢ 7.1¢ $4.091K 54.95K

Buyers (Bids)

No. Vol. Price($)
1 198734 7.0¢
 

Sellers (Offers)

Price($) Vol. No.
7.4¢ 29802 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.